A new herpes drug called ASP2151 could be a brilliant new alternative to the popular antiviral drugs acyclovir or Valtrex. The drug uses a different method to attack the herpes virus and may prevent visible symptoms much more effectively than any other currently available therapeutics.
ASP2151 is a long-awaited helicase primase inhibitor (HPI) drug.
The recent quarterly statement for Astellas brings encouraging news, suggesting that ASP2151 is now going into phase III trials.
第三阶段的测试是不是意味着马上就能上市那？
